Targeting Histone Modifications in Bone and Lung Metastatic Cancers.
Courtney M EdwardsRachelle W JohnsonPublished in: Current osteoporosis reports (2021)
Preclinical studies have demonstrated that the role for HDACs is highly dependent on tumor type and stage of disease progression. HDAC inhibitors can induce apoptosis, senescence, cell differentiation, and tumor dormancy genes and inhibit angiogenesis, making these promising therapeutics for the treatment of metastatic disease. HDAC inhibitors are already FDA approved for hematologic malignancies and are in clinical trials with standard-of-care chemotherapies and targeted agents for several solid tumors, including cases of metastatic disease. However, these drugs can negatively impact bone homeostasis. Although HDAC inhibitors are not currently administered for the treatment of bone and lung metastatic disease, preclinical studies have shown that these drugs can reduce distant metastasis by targeting molecular factors and signaling pathways that drive tumor cell dissemination to these sites. Thus, HDAC inhibitors in combination with bone protective therapies may be beneficial in the treatment of bone metastatic cancers.
Keyphrases
- small cell lung cancer
- squamous cell carcinoma
- bone mineral density
- clinical trial
- histone deacetylase
- healthcare
- soft tissue
- bone loss
- oxidative stress
- endothelial cells
- dna methylation
- stem cells
- cell therapy
- bone regeneration
- palliative care
- dna damage
- cancer therapy
- combination therapy
- transcription factor
- small molecule
- endoplasmic reticulum stress
- health insurance
- young adults
- single cell
- stress induced
- cell proliferation
- replacement therapy
- induced apoptosis